Published in AIDS Weekly, February 21st, 2005
This award continues the divisional prosecution of an original application filed March 3, 1999. The specific award covers the use of Ii-Key peptide homologs to inhibit antigen presentation. It bears on potential treatments of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and diabetes mellitus.
Dr. Robert Humphreys, the chief scientific officer of Antigen Express has spent his lifetime understanding how antigenic peptides are presented to the immune system...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.